In this article, we will be taking a look at the 11 Best Performing Biotech Stocks So Far in 2025. CRISPR Therapeutics AG ...

CRISPR Therapeutics AG (CRSP) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to ...

Gene-edited pancreatic cells have been transplanted into a patient with type 1 diabetes for the first time. They produced ...

Horses with genomic edits to make them run faster have been banned from polo, but a zoo of CRISPR-edited animals is gaining ...

Edits create cells that don’t trigger an immune response, allowing implant recipient to forego immune-suppressing drugs.

Investigators have used base editing to create a treatment for multisystemic smooth muscle dysfunction syndrome, which has ...

Editas' share price has struggled due to clinical setbacks, but recent focus on in-vivo gene editing offers renewed hope and upside potential. The company is valued near cash levels, with $221M on ...

The latest Crispr Technology Market research report offers crucial insights into how the industry is evolving, highlighting key drivers of growth and the main revenue streams expected between 2025 and ...

KJ Muldoon recently made history by becoming the first patient to receive a personalized CRISPR gene therapy, designed specifically for the genetic mutations causing his rare metabolic disease. Now, a ...

With the power to rewrite the genetic code underlying countless diseases, CRISPR holds immense promise to revolutionize medicine. But until scientists can deliver its gene-editing machinery safely and ...